Mina Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mina Tao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Guoli Li
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
1 shared publication Huifang Tan
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University
1 shared publication- Mengjiao Wei
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University
1 shared publication - Yinyin Chen
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University
1 shared publication Yiya Yang
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University
1 shared publicationZheng Xiao
Department of Nephrology, Hunan Clinical Research Center for Chronic Kidney Disease, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University
1 shared publication
Latest Publications
- Open Access
- 9 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2652826
Emerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target
ATP-citrate lyase (ACLY) is a crucial cytosolic and nuclear enzyme that catalyzes the synthesis of acetyl-CoA from citrate, serving as a central metabolic node linking carbohydrate metabolism to de novo lipogenesis and histone acetylation. Accumulating evidence positions ACLY not merely as a metabolic enzyme but as a key pathogenic driver in various kidney diseases. This review systematically examines the multifaceted roles of ACLY in renal physiology and pathology. During development, ACLY is essential for nephron progenitor cell maintenance and nephrogenesis. In diabetic kidney disease, hyperglycemia upregulates and promotes nuclear translocation of ACLY, fueling histone acetylation and the transcription of pro-fibrotic genes, while also contributing to oxidative stress and lipid peroxidation. In obesity-related kidney injury, ACLY drives renal ectopic lipid accumulation and inflammation by providing substrates for adipogenic enzymes and inducing histone hyperacetylation. ACLY also promotes renal fibrosis in chronic kidney disease via pathways such as AKT/ACLY signaling. In clear cell renal cell carcinoma, ACLY expression is upregulated through HIF-2α/LPCAT1/FBXW7 and VHL/PPARγ axes, promoting lipid synthesis, tumor proliferation, and metastasis. Furthermore, ACLY activity influences hypocitraturia, a key factor in nephrolithiasis, and is upregulated in polycystic kidney disease, where its inhibition attenuates cystic growth. Given its central role across diverse renal pathologies, ACLY emerges as a promising therapeutic target. Several inhibitors, including bempedoic acid, SB-204990, and natural compounds, show potential in modulating ACLY activity. This review consolidates current knowledge on ACLY in kidney diseases, highlighting its mechanistic contributions, and underscoring its significant potential for diagnostic and therapeutic innovation.
- 9 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2652826
Open AccessEmerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target
ATP-citrate lyase (ACLY) is a crucial cytosolic and nuclear enzyme that catalyzes the synthesis of acetyl-CoA from citrate, serving as a central metabolic node linking carbohydrate metabolism to de novo lipogenesis and histone acetylation. Accumulating evidence positions ACLY not merely as a metabolic enzyme but as a key pathogenic driver in various kidney diseases. This review systematically examines the multifaceted roles of ACLY in renal physiology and pathology. During development, ACLY is essential for nephron progenitor cell maintenance and nephrogenesis. In diabetic kidney disease, hyperglycemia upregulates and promotes nuclear translocation of ACLY, fueling histone acetylation and the transcription of pro-fibrotic genes, while also contributing to oxidative stress and lipid peroxidation. In obesity-related kidney injury, ACLY drives renal ectopic lipid accumulation and inflammation by providing substrates for adipogenic enzymes and inducing histone hyperacetylation. ACLY also promotes renal fibrosis in chronic kidney disease via pathways such as AKT/ACLY signaling. In clear cell renal cell carcinoma, ACLY expression is upregulated through HIF-2α/LPCAT1/FBXW7 and VHL/PPARγ axes, promoting lipid synthesis, tumor proliferation, and metastasis. Furthermore, ACLY activity influences hypocitraturia, a key factor in nephrolithiasis, and is upregulated in polycystic kidney disease, where its inhibition attenuates cystic growth. Given its central role across diverse renal pathologies, ACLY emerges as a promising therapeutic target. Several inhibitors, including bempedoic acid, SB-204990, and natural compounds, show potential in modulating ACLY activity. This review consolidates current knowledge on ACLY in kidney diseases, highlighting its mechanistic contributions, and underscoring its significant potential for diagnostic and therapeutic innovation.